Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Fast Track Articles
  5. Fast Track Article
image of Safety Profile of Statins for Post-Marketing Adverse Cardiovascular Events: A Real-World Pharmacovigilance Analysis
file format pdf download PDF

Abstract

Aims and objectives

The purpose of this study was to comprehensively evaluate the association of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) with neurological adverse events using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, with the aim of guiding the rational use of statins.

Methods

The number and clinical characteristics of adverse events (AEs) to statins in the FAERS database between 2012 and March, 2023, were extracted. Neurological AEs were defined by the system organ classes (SOCs) of “Nervous System Disorders (10029205)” and the corresponding PT. Disproportionality was calculated using the reporting dominance ratio (ROR), proportional reporting ratio (PRR), and information component (IC).

Results

Between January, 2012 and March, 2023, a total of 90,357 AEs were reported for the three statins (atorvastatin, resuvastatin, and simvastatin). The majority of reports on AEs came from the United States (n=7284). A total of 8409 reports described neurological AEs following the use of the three statins, with atorvastatin accounting for more than half of the reports (n=4430). The mean age of patients who developed neurological AEs was 55 years and older. The prevalence was similar in female patients (2230/4480) and male patients (1999/4480). Disproportionate analyses showed that at the SOC level, only the correlation between atorvastatin and neurological AEs suggested a positive signal (ROR: 9.77 (9.56-9.99); IC: 3.28; PRR (χ2): 9.76 (16.07)) and in total, there were 32 PTs with a positive signal. The median time for neurological AEs was 71 days (IQR: 14-559 days), and the most common AEs were other serious effects (important medical event) (OT) (n=2283) and hospitalization (HO) (n=715).

Conclusion

This study suggests that atorvastatin may be associated with an increased risk of neurological AEs. This study provides realistic evidence of the potential risk of statin-related adverse events.

© 2024 Bentham Science Publishers
© 2024 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303324204240905111835
2024-10-28
2024-11-29

  • From This Site

    /content/journals/emiddt/10.2174/0118715303324204240905111835
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/10.2174/0118715303324204240905111835/BMS-EMIDDT-2024-186.html?itemId=/content/journals/emiddt/10.2174/0118715303324204240905111835&mimeType=html&fmt=ahah

References

  1. Granat M.M. Eifler-Zydel J. Kolmas J. Statins—their role in bone tissue metabolism and local applications with different carriers. Int. J. Mol. Sci. 2024 25 4 2378 10.3390/ijms25042378 38397055
    [Google Scholar]
  2. Ray K.K. Nicholls S.J. Li N. Louie M.J. Brennan D. Lincoff A.M. Nissen S.E. Efficacy and safety of bempedoic acid among patients with and without diabetes: Prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024 12 1 19 28 10.1016/S2213‑8587(23)00316‑9 38061370
    [Google Scholar]
  3. DTB Team Ezetimibe plus moderate-intensity statin versus high-intensity statin. Drug Ther. Bull. 2023 61 3 38 10.1136/dtb.2023.000008 36813278
    [Google Scholar]
  4. Walker A.J. Zhu J. Thoma F. Marroquin O. Makani A. Gulati M. Gianos E. Virani S.S. Rodriguez F. Reis S.E. Ballantyne C. Mulukutla S. Saeed A. Statin utilization and cardiovascular outcomes in a real-world primary prevention cohort of older adults. Am. J. Prevent. Cardiol. 2024 18 100664 10.1016/j.ajpc.2024.100664 38665251
    [Google Scholar]
  5. Qiu J. Wei L. Su Y. Tang Y. Peng G. Wu Y. He Y. Liu H. Guo W. Wu Z. Xu P. Mo M. Lipid metabolism disorder in cerebrospinal fluid related to parkinson’s disease. Brain Sci. 2023 13 8 1166 10.3390/brainsci13081166 37626522
    [Google Scholar]
  6. Litvinova O. Yeung A.W.K. Hammerle F.P. Mickael M.E. Matin M. Kletecka-Pulker M. Atanasov A.G. Willschke H. Digital technology applications in the management of adverse drug reactions: Bibliometric analysis. Pharmaceuticals (Basel) 2024 17 3 395 10.3390/ph17030395 38543181
    [Google Scholar]
  7. Raschi E. Salvo F. Bate A. De Ponti F. Poluzzi E. Tuccori M. van Puijenbroek E. Joshi N. Khouri C. Peer review in pharmacovigilance: Lens on disproportionality analysis. Drug Saf. 2024 47 7 601 605 10.1007/s40264‑024‑01419‑3 38498258
    [Google Scholar]
  8. Salvo F. Micallef J. Lahouegue A. Chouchana L. Létinier L. Faillie J.L. Pariente A. Will the future of pharmacovigilance be more automated? Expert Opin. Drug Saf. 2023 22 7 541 548 10.1080/14740338.2023.2227091 37435796
    [Google Scholar]
  9. Jung J. Shin S. Park J. Lee K. Choi H.Y. Hypotensive and vasorelaxant effects of sanguisorbae radix ethanol extract in spontaneously hypertensive and sprague dawley rats. Nutrients 2023 15 21 4510 10.3390/nu15214510 37960162
    [Google Scholar]
  10. Liu M. Gu L. Zhang Y. Zhou H. Wang Y. Xu Z.X. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system. Front. Pharmacol. 2024 15 1290975 10.3389/fphar.2024.1290975 38357304
    [Google Scholar]
  11. Nacchia A. Franco A. Cicione A. Riolo S. Santoro G. Romagnoli M. Sarcinelli L. Fiasconaro D. Ghezzo N. Gallo G. Tema G. Pastore A.L. Salhi Y.A. Fuschi A. Carbone A. Franco G. Lombardo R. Tubaro A. De Nunzio C. Medications mostly associated with ejaculatory disorders: Assessment of the eudra-vigilance and food and drug administration pharmacovigilance databases entries. Urology 2024 185 59 64 10.1016/j.urology.2023.12.021 38331221
    [Google Scholar]
  12. Lu H. Zhang Y. Liu P. Identifying new safety risk of human serum albumin: A retrospective study of real-world data. Front. Pharmacol. 2024 15 1319900 10.3389/fphar.2024.1319900 38292942
    [Google Scholar]
  13. Battini V. Carnovale C. Clementi E. Sessa M. Ubrogepant and rimegepant: Signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System. Expert Opin. Drug Saf. 2023 22 11 1105 1112 10.1080/14740338.2023.2223958 37293948
    [Google Scholar]
  14. Zou F. Zhu C. Lou S. Cui Z. Wang D. Ou Y. Wang L. Chen J. Lan Y. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front. Pharmacol. 2023 14 1320458 10.3389/fphar.2023.1320458 38186645
    [Google Scholar]
  15. Sacchi de Camargo Correia G. Pai T. Li S. Connor D. Zhao Y. Lou Y. Manochakian R. Immune-related adverse events in patients with lung cancer. Curr. Oncol. Rep. 2023 25 11 1259 1275 10.1007/s11912‑023‑01462‑w 37782426
    [Google Scholar]
  16. Ataei S. Makki B. Ayubi E. Emami S. Medication discrepancies identified by medication reconciliation among patients with acute coronary syndrome. Naunyn-Schmiedeberg's Archives of Pharmacology ChamSpringer 2024 10.1007/s00210‑024‑03114‑7 38695910
    [Google Scholar]
  17. Ernst M. Folkerts A.K. Gollan R. Lieker E. Caro-Valenzuela J. Adams A. Cryns N. Monsef I. Dresen A. Roheger M. Eggers C. Skoetz N. Kalbe E. Physical exercise for people with Parkinson’s disease: A systematic review and network meta-analysis. Cochrane Database Syst. Rev. 2023 1 1 CD013856 36602886
    [Google Scholar]
  18. Yang H. Wan Z. Chen M. Zhang X. Cui W. Zhao B. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database. Expert Opin. Drug Metab. Toxicol. 2023 19 4 217 223 10.1080/17425255.2023.2219390 37243615
    [Google Scholar]
  19. van den Ouweland F. Charpentier N. Türeci Ö. Rizzi R. Mensa F.J. Lindemann C. Pather S. Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data. Hum. Vaccin. Immunother. 2024 20 1 2315659 10.1080/21645515.2024.2315659 38407186
    [Google Scholar]
  20. Mhaimeed O. Burney Z.A. Schott S.L. Kohli P. Marvel F.A. Martin S.S. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better. Am. J. Prevent. Cardiol. 2024 18 100649 10.1016/j.ajpc.2024.100649 38576462
    [Google Scholar]
  21. Yan Z. Xu Y. Li K. Liu L. Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: A mendelian randomization study. Acta Neurol. Belg. 2024 124 2 485 494 10.1007/s13760‑023‑02393‑w 37889424
    [Google Scholar]
  22. Luca A.C. David S.G. David A.G. Țarcă V. Pădureț I.A. Mîndru D.E. Roșu S.T. Roșu E.V. Adumitrăchioaiei H. Bernic J. Cojocaru E. Țarcă E. Atherosclerosis from newborn to adult—epidemiology, pathological aspects, and risk factors. life (basel) 2023 13 10 2056 10.3390/life13102056 37895437
    [Google Scholar]
  23. Park S. Hwang D. Kang J. Han J.K. Yang H.M. Park K.W. Kang H.J. Koo B.K. Cho J.M. Cho B.R. Ahn S.G. Kang S.M. Sung J.H. Kim U. Lee N. Kim H.S. Efficacy and safety of triple therapy of telmisartan/amlodipine/rosuvastatin in patients with dyslipidemia and hypertension: A multicenter randomized clinical trial. Curr. Ther. Res. Clin. Exp. 2024 100 100735 10.1016/j.curtheres.2024.100735 38380420
    [Google Scholar]
  24. Lee J.Y. Harney D.J. Teo J.D. Kwok J.B. Sutherland G.T. Larance M. Don A.S. The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus. Mol. Neurodegener. 2023 18 1 63 10.1186/s13024‑023‑00650‑3 37726834
    [Google Scholar]
  25. Gangoda D.M. Saiyed M.S. Pathan S.R. Sharma K.B. Patel V.A. Sachdeva P.D. Patel M.Y. Patel M.D. Enhanced neuroprotective synergy of atorvastatin and magnesium L-threonate in a rat model of alzheimer’s disease induced by aluminum chloride. Cureus 2023 15 11 e48400 10.7759/cureus.48400 38074017
    [Google Scholar]
  26. Cerf M.E. Maternal and child health, non-communicable diseases and metabolites. Metabolites 2023 13 6 756 10.3390/metabo13060756 37367913
    [Google Scholar]
  27. Djuricic I. Calder P.C. Omega-3 (n-3) fatty acid–statin interaction: Evidence for a novel therapeutic strategy for atherosclerotic cardiovascular disease. Nutrients 2024 16 7 962 10.3390/nu16070962 38612996
    [Google Scholar]
  28. Weekman E.M. Johnson S.N. Rogers C.B. Sudduth T.L. Xie K. Qiao Q. Fardo D.W. Bottiglieri T. Wilcock D.M. Atorvastatin rescues hyperhomocysteinemia-induced cognitive deficits and neuroinflammatory gene changes. J. Neuroinflammation 2023 20 1 199 10.1186/s12974‑023‑02883‑x 37658433
    [Google Scholar]
  29. Xiong Q. Sun H. Wang Y. Xu Q. Zhang Y. Xu M. Zhao Z. Li P. Wu C. Lipid droplet accumulation in Wdr45-deficient cells caused by impairment of chaperone-mediated autophagic degradation of Fasn. Lipids Health Dis. 2024 23 1 91 10.1186/s12944‑024‑02088‑y 38539242
    [Google Scholar]
  30. Lee W. Kang S.H. Kim S.H. Lee S.Y. Myung W. Jheon K.H. Yoon C.H. Suh J.W. Youn T.J. Chae I.H. Impact of dementia and drug compliance on patients with acute myocardial infarction. Clin. Cardiol. 2023 46 10 1253 1259 10.1002/clc.24091 37488767
    [Google Scholar]
  31. Liu W. Yang C. Lei F. Huang X. Cai J. Chen S. She Z.G. Li H. Major lipids and lipoprotein levels and risk of blood pressure elevation: A Mendelian Randomisation study. EBioMedicine 2024 100 104964 10.1016/j.ebiom.2023.104964 38181703
    [Google Scholar]
  32. Park C.H.K. Kim D. Kim B. Rhee S.J. Cho S.J. Ahn Y.M. Serum lipids as predictive markers for death by suicide. Psychiatry Res. 2024 335 115837 10.1016/j.psychres.2024.115837 38492263
    [Google Scholar]
  33. Huang H.H. Ma K.S.K. Wu M.Y. Hung Y.M. Tsao C.H. Wei J.C.C. Wen W.S. Wang Y.H. Hung S.Y. Chao M.M. Patients with obstructive sleep apnea are at great risk of flavor disorders: A 15-year population-based cohort study. Clin. Oral Investig. 2022 27 1 183 192 10.1007/s00784‑022‑04707‑3 36129542
    [Google Scholar]
  34. Al-Shalchi R.F. Mohammad F.K. Adverse neurobehavioral changes with reduced blood and brain cholinesterase activities in mice treated with statins. Vet. World 2024 17 1 82 88 10.14202/vetworld.2024.82‑88 38406368
    [Google Scholar]
  35. Goldstein L.B. Toth P.P. Dearborn-Tomazos J.L. Giugliano R.P. Hirsh B.J. Peña J.M. Selim M.H. Woo D. Aggressive LDL-C lowering and the brain: Impact on risk for dementia and hemorrhagic stroke: A Scientific Statement From the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 2023 43 10 e404 e442 10.1161/ATV.0000000000000164 37706297
    [Google Scholar]
  36. Golomb B.A. Han J.H. Langsjoen P.H. Dinkeloo E. Zemljic-Harpf A.E. Statin use in relation to COVID-19 and other respiratory infections: Muscle and other considerations. J. Clin. Med. 2023 12 14 4659 10.3390/jcm12144659 37510774
    [Google Scholar]
  37. Shao M. Wang M. Wang X. Feng X. Zhang L. Lv H. SQLE is a promising prognostic and immunological biomarker and correlated with immune Infiltration in Sarcoma. Medicine (Baltimore) 2024 103 6 e37030 10.1097/MD.0000000000037030 38335381
    [Google Scholar]
  38. Li D. Xu T. Xie D. Wang M. Sun S. Wang M. Zhang S. Yang X. Zhang Z. Wang S. Kuang M. Tang J. Liu H. Hong X. Fu G. Zhang W. Efficacy of mobile-based cognitive behavioral therapy on lowering low-density lipoprotein cholesterol levels in patients with atherosclerotic cardiovascular disease: Multicenter, prospective randomized controlled trial. J. Med. Internet Res. 2023 25 e44939 10.2196/44939 37043273
    [Google Scholar]
  39. Hayıroğlu M.İ. Şaylık F. Çınar T. Tokgözoğlu L. Meta-analysis of the Current Research on the Relationship Between Blood Lipid Levels and the Occurrence of Atrial Fibrillation. Heart Lung Circ. 2023 32 10 1158 1166 10.1016/j.hlc.2023.08.006 37741751
    [Google Scholar]
  40. Du W. Yan C. Wang Y. Song C. Li Y. Tian Z. Liu Y. Shen W. Association between dietary magnesium intake and gallstones: The mediating role of atherogenic index of plasma. Lipids Health Dis. 2024 23 1 82 10.1186/s12944‑024‑02074‑4 38509591
    [Google Scholar]
  41. Chbeir S. Carrión V. Resilience by design: How nature, nurture, environment, and microbiome mitigate stress and allostatic load. World J. Psychiatry 2023 13 5 144 159 10.5498/wjp.v13.i5.144 37303926
    [Google Scholar]
  42. Bălănescu A. Bălănescu P.C. Codreanu I.F. Stan I.V. Comanici V.D. Robu A.M. Ciomârtan T. Exploring the role of serum osteonectin and Hsp27 in pediatric MAFLD diagnosis and cardiometabolic health. Nutrients 2024 16 6 866 10.3390/nu16060866 38542777
    [Google Scholar]
  43. Blanchard J.W. Bula M. Davila-Velderrain J. Akay L.A. Zhu L. Frank A. Victor M.B. Bonner J.M. Mathys H. Lin Y.T. Ko T. Bennett D.A. Cam H.P. Kellis M. Tsai L.H. Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes. Nat. Med. 2020 26 6 952 963 10.1038/s41591‑020‑0886‑4 32514169
    [Google Scholar]
  44. Seidita A Cusimano A Giuliano A Oxidative Stress as a Target for Non-Pharmacological Intervention in MAFLD: Could There Be a Role for EVOO? Antioxidants (Basel) 2024 13 6 731
    [Google Scholar]
  45. Arrieche D. Olea A.F. Jara-Gutiérrez C. Villena J. Pardo-Baeza J. García-Davis S. Viteri R. Taborga L. Carrasco H. Ethanolic extract from fruits of Pintoa chilensis, a Chilean Extremophile Plant. Plants 2024 13 10 1409 10.3390/plants13101409 38794478
    [Google Scholar]
  46. Manolaras I. Del Bondio A. Griso O. Reutenauer L. Eisenmann A. Habermann B.H. Puccio H. Mitochondrial dysfunction and calcium dysregulation in COQ8A -ataxia Purkinje neurons are rescued by CoQ10 treatment. Brain 2023 146 9 3836 3850 10.1093/brain/awad099 36960552
    [Google Scholar]
/content/journals/emiddt/10.2174/0118715303324204240905111835
Loading
Safety Profile of Statins for Post-Marketing Adverse Cardiovascular Events: A Real-World Pharmacovigilance Analysis
Bentham Science Publishers ; https://doi.org/10.2174/0118715303324204240905111835
/content/journals/emiddt/10.2174/0118715303324204240905111835
/content/journals/emiddt/10.2174/0118715303324204240905111835
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: atorvastatin ; Statins ; neurological ; real-world study ; FDA Adverse Event Reporting System ; adverse events

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test